Dietary galacto-oligosaccharides prevent airway eosinophilia and hyperresponsiveness in a murine house dust mite-induced asthma model

Respiratory Research

Gert Folkerts³  Aletta D Kraneveld³  Johan Garssen¹  Dianne JM Delsing⁴  Thea Leusink-Muis³  Saskia Braber²  Linette EM Willemsen³  Kim AT Verheijden³ 

[1] Nutricia Research, Immunology, Utrecht, The Netherlands;Division of Veterinary Pharmacy, Pharmacology and Toxicology, Utrecht University, Faculty of Veterinary Sciences, Utrecht, The Netherlands;Department of Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Faculty of Science, Utrecht, The Netherlands;FrieslandCampina, Amersfoort, The Netherlands

关键词: Budesonide;    Galacto-oligosaccharide;    House dust mite;    Asthma;   

Others  :  1133504
DOI  :  10.1186/s12931-015-0171-0

 received in 2014-08-07, accepted in 2015-01-17,  发布年份 2015

【 摘 要 】

Background

Allergic asthma is strongly associated with the exposure to house dust mite (HDM) and is characterized by eosinophilic pulmonary inflammation and airway hyperresponsiveness (AHR). Recently, there is an increased interest in using dietary oligosaccharides, also known as prebiotics, as a novel strategy to prevent the development of, or reduce, symptoms of allergy.

Aim

We investigated the preventive capacity of dietary galacto-oligosaccharides (GOS) compared to an intra-airway therapeutic treatment with budesonide on the development of HDM-induced allergic asthma in mice.

Methods

BALB/c mice were intranasally sensitized with 1 μg HDM on day 0 followed by daily intranasal challenge with PBS or 10 μg HDM on days 7 to 11. Two weeks prior to the first sensitization and throughout the experiment mice were fed a control diet or a diet containing 1% GOS. Reference mice were oropharyngeally instilled with budesonide (500 μg/kg) on days 7, 9, 11, and 13, while being fed the control diet. On day 14, AHR was measured by nebulizing increasing doses of methacholine into the airways. At the end of the experiment, bronchoalveolar lavage fluid (BALF) and lungs were collected.

Results

Sensitization and challenge with HDM resulted in AHR. In contrast to budesonide, dietary intervention with 1% GOS prevented the development of AHR. HDM sensitization and challenge resulted in a significant increase in BALF leukocytes numbers, which was suppressed by budesonide treatment and dietary intervention with 1% GOS. Moreover, HDM sensitization and challenge resulted in significantly enhanced concentrations of IL-6, CCL17, IL-33, CCL5 and IL-13 in lung tissue. Both dietary intervention with 1% GOS or budesonide treatment significantly decreased the HDM-induced increased concentrations of CCL5 and IL-13 in lung tissue, while budesonide also reduced the HDM-enhanced concentrations of IL-6 and CCL17 in lung tissue.

Conclusion

Not only did dietary intervention with 1% GOS during sensitization and challenge prevent the induction of airway eosinophilia and Th2-related cytokine and chemokine concentrations in the lung equally effective as budesonide treatment, it also prevented AHR development in HDM-allergic mice. GOS might be useful for the prevention and/or treatment of symptoms in asthmatic disease.

【 授权许可】

   
2015 Verheijden et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Holgate ST: Innate and adaptive immune responses in asthma. Nat Med 2012, 18(5):673-83.
• [2]WHO: [http://www.who.int/mediacentre/factsheets/fs307/en/index.html].
• [3]Barnes PJ: Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008, 8(3):183-92.
• [4]Liew FY, Pitman NI, McInnes IB: Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10(2):103-10.
• [5]Miller AM: Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011, 8(1):22-9255-8-22. BioMed Central Full Text
• [6]Salazar F, Ghaemmaghami AM: Allergen recognition by innate immune cells: critical role of dendritic and epithelial cells. Front Immunol 2013, 4:356.
• [7]Holgate ST: Mechanisms of asthma and implications for its prevention and treatment: a personal journey. Allergy Asthma Immunol Res 2013, 5(6):343-7.
• [8]Kudo M, Ishigatsubo Y, Aoki I: Pathology of asthma. Front Microbiol 2013, 4:263.
• [9]Dimov VV, Casale TB: Immunomodulators for asthma. Allergy Asthma Immunol Res 2010, 2(4):228-34.
• [10]Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW: Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res 2001, 2(2):71-9. BioMed Central Full Text
• [11]Nials AT, Uddin S: Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech 2008, 1(4–5):213-20.
• [12]Rincon M, Irvin CG: Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci 2012, 8(9):1281-90.
• [13]Hammad H, Lambrecht BN: Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev Immunol 2008, 8(3):193-204.
• [14]Barnes PJ: New therapies for asthma: is there any progress? Trends Pharmacol Sci 2010, 31(7):335-43.
• [15]Tamm M, Richards DH, Beghe B, Fabbri L: Inhaled corticosteroid and long-acting beta2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med 2012, 106(Suppl 1):S9-19.
• [16]Vazquez-Tello A, Halwani R, Hamid Q, Al-Muhsen S: Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells. J Clin Immunol 2013, 33(2):466-78.
• [17]Gourbeyre P, Denery S, Bodinier M: Probiotics, prebiotics, and synbiotics: impact on the gut immune system and allergic reactions. J Leukoc Biol 2011, 89(5):685-95.
• [18]Noverr MC, Huffnagle GB: Does the microbiota regulate immune responses outside the gut? Trends Microbiol 2004, 12(12):562-8.
• [19]Vieira WA, Pretorius E: The impact of asthma on the gastrointestinal tract (GIT). J Asthma Allergy 2010, 3:123-30.
• [20]Gibson GR, Roberfroid MB: Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995, 125(6):1401-12.
• [21]Jeurink PV, van Esch BC, Rijnierse A, Garssen J, Knippels LM: Mechanisms underlying immune effects of dietary oligosaccharides. Am J Clin Nutr 2013, 98(2):572S-7.
• [22]Ladirat SE, Schoterman MH, Rahaoui H, Mars M, Schuren FH, Gruppen H, et al.: Exploring the effects of galacto-oligosaccharides on the gut microbiota of healthy adults receiving amoxicillin treatment. Br J Nutr 2014, 112(4):536-46.
• [23]Ladirat SE, Schuren FH, Schoterman MH, Nauta A, Gruppen H, Schols HA: Impact of galacto-oligosaccharides on the gut microbiota composition and metabolic activity upon antibiotic treatment during in vitro fermentation. FEMS Microbiol Ecol 2014, 87(1):41-51.
• [24]Schouten B, van Esch BC, Hofman GA, van Doorn SA, Knol J, Nauta AJ, et al.: Cow milk allergy symptoms are reduced in mice fed dietary synbiotics during oral sensitization with whey. J Nutr 2009, 139(7):1398-403.
• [25]van de Pol MA, Lutter R, Smids BS, Weersink EJ, van der Zee JS: Synbiotics reduce allergen-induced T-helper 2 response and improve peak expiratory flow in allergic asthmatics. Allergy 2011, 66(1):39-47.
• [26]Vos AP, van Esch BC, Stahl B, M’Rabet L, Folkerts G, Nijkamp FP, et al.: Dietary supplementation with specific oligosaccharide mixtures decreases parameters of allergic asthma in mice. Int Immunopharmacol 2007, 7(12):1582-7.
• [27]Sagar S, Vos AP, Morgan ME, Garssen J, Georgiou NA, Boon L, et al.: The combination of Bifidobacterium breve with non-digestible oligosaccharides suppresses airway inflammation in a murine model for chronic asthma. Biochim Biophys Acta 2014, 1842(4):573-83.
• [28]Sagar S, Morgan ME, Chen S, Vos AP, Garssen J, van Bergenhenegouwen J, et al.: Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma. Respir Res 2014, 15(1):46. BioMed Central Full Text
• [29]De Alba J, Raemdonck K, Dekkak A, Collins M, Wong S, Nials AT, et al.: House dust mite induces direct airway inflammation in vivo: implications for future disease therapy? Eur Respir J 2010, 35(6):1377-87.
• [30]Kool M, Willart MA, van Nimwegen M, Bergen I, Pouliot P, Virchow JC, et al.: An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 2011, 34(4):527-40.
• [31]Braber S, Overbeek SA, Koelink PJ, Henricks PA, Zaman GJ, Garssen J, et al.: CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1. Eur J Pharmacol 2011, 668(3):443-9.
• [32]Sagar S, Verheijden KA, Georgiou NA, Garssen J, Kraneveld AD, Vos AP, et al.: Differential regulation of inflammation and immunity in mild and severe experimental asthma. Mediators Inflamm 2013, 2013:808470.
• [33]Braber S, Koelink PJ, Henricks PA, Jackson PL, Nijkamp FP, Garssen J, et al.: Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. Am J Physiol Lung Cell Mol Physiol 2011, 300(2):L255-65.
• [34]Koelink PJ, Overbeek SA, Braber S, Morgan ME, Henricks PA, Roda MA, Verspaget HW, Wolfkamp SC, Te Velde AA, Jones CW, Jackson PL, Blalock JE, Sparidans RW, Kruijtzer JA, Garssen J, Folkerts G, Kraneveld AD: Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut 2014, 63(4):578-87.
• [35]Tomlinson KL, Davies GC, Sutton DJ, Palframan RT. Neutralisation of interleukin-13 in mice prevents airway pathology caused by chronic exposure to house dust mite. PLoS One 2010, 5(10): doi:10.1371/journal.pone.0013136.
• [36]Gregory LG, Lloyd CM: Orchestrating house dust mite-associated allergy in the lung. Trends Immunol 2011, 32(9):402-11.
• [37]Yokoyama A, Kohno N, Fujino S, Hamada H, Inoue Y, Fujioka S, et al.: Circulating interleukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med 1995, 151(5):1354-8.
• [38]van der Velden VH: Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma. Mediators Inflamm 1998, 7(4):229-37.
• [39]Mattoli S, Marini M, Fasoli A: Expression of the potent inflammatory cytokines, GM-CSF, IL6, and IL8, in bronchial epithelial cells of asthmatic patients. Chest 1992, 101(3 Suppl):27S-9.
• [40]Hartl D, Lee CG, Da Silva CA, Chupp GL, Elias JA: Novel biomarkers in asthma: chemokines and chitinase-like proteins. Curr Opin Allergy Clin Immunol 2009, 9(1):60-6.
• [41]Vijayanand P, Durkin K, Hartmann G, Morjaria J, Seumois G, Staples KJ, et al.: Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients. J Immunol 2010, 184(8):4568-74.
• [42]Leung TF, Wong CK, Chan IH, Ip WK, Lam CW, Wong GW: Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma. J Allergy Clin Immunol 2002, 110(3):404-9.
• [43]Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al.: Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008, 20(6):791-800.
• [44]Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY: IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol 2010, 185(6):3472-80.
• [45]Borish L, Steinke JW: Interleukin-33 in asthma: how big of a role does it play? Curr Allergy Asthma Rep 2011, 11(1):7-11.
• [46]Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, et al.: Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010, 125(3):752-4.
• [47]Deckers J, Branco Madeira F, Hammad H: Innate immune cells in asthma. Trends Immunol 2013, 34(11):540-7.
• [48]Lukacs NW: Role of chemokines in the pathogenesis of asthma. Nat Rev Immunol 2001, 1(2):108-16.
• [49]Schuijs MJ, Willart MA, Hammad H, Lambrecht BN: Cytokine targets in airway inflammation. Curr Opin Pharmacol 2013, 13(3):351-61.
• [50]Goplen N, Karim MZ, Liang Q, Gorska MM, Rozario S, Guo L, et al.: Combined sensitization of mice to extracts of dust mite, ragweed, and Aspergillus species breaks through tolerance and establishes chronic features of asthma. J Allergy Clin Immunol 2009, 123(4):925–32.e11.
• [51]Ingram JL, Kraft M: IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012, 130(4):829-42. quiz 843–4
• [52]Wills-Karp M: Interleukin-13 in asthma pathogenesis. Immunol Rev 2004, 202:175-90.